atai Life Sciences announces Phase 2 study of EMP-01 for social anxiety disorder, with results expected in Q1 2026. atai Life Sciences has announced the dosing of the first patient in a Phase 2 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback